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Background-—Clinical guidelines recommend using predicted atherosclerotic cardiovascular disease (ASCVD) risk to inform
treatment decisions. The objective was to compare the contribution of changes in modifiable risk factors versus aging to the
development of high 10-year predicted ASCVD risk.
Methods and Results-—A prospective follow-up was done of the Jackson Heart Study, an exclusively black cohort at visit 1 (2000–
2004) and visit 3 (2009–2012). Analyses included 1115 black participants without high 10-year predicted ASCVD risk (<7.5%),
hypertension, diabetes mellitus, or ASCVD at visit 1. We used the Pooled Cohort equations to calculate the incidence of high (≥7.5%)
10-year predicted ASCVD risk at visit 3. We recalculated the percentage with high 10-year predicted ASCVD risk at visit 3 assuming
each risk factor (age, systolic blood pressure, antihypertensive medication use, diabetes mellitus, smoking, total and high-density
lipoprotein cholesterol), one at a time, did not change from visit 1. Themean age at visit 1 was 45.29.5 years. Overall, 30.9% (95% CI
28.3–33.4%) of participants developed high 10-year predicted ASCVD risk. Aging accounted for 59.7% (95% CI 54.2–65.1%) of the
development of high 10-year predicted ASCVD risk compared with 32.8% (95% CI 27.0–38.2%) for increases in systolic blood pressure
or antihypertensive medication initiation and 12.8% (95% CI 9.6–16.5%) for incident diabetes mellitus. Among participants <50 years,
the contribution of increases in systolic blood pressure or antihypertensive medication initiation was similar to aging.
Conclusions-—Increases in systolic blood pressure and antihypertensive medication initiation are major contributors to the
development of high 10-year predicted ASCVD risk in blacks, particularly among younger adults. ( J Am Heart Assoc. 2017;6:
e005054. DOI: 10.1161/JAHA.116.005054.)
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S everal clinical practice guidelines recommend usingpredicted atherosclerotic cardiovascular disease (ASCVD)
risk to inform treatment initiation decisions.1–3 Age is a major
nonmodifiable risk factor for ASCVD and a component of
virtually all ASCVD risk prediction equations.4,5 Predicted
ASCVD risk is also determined by modifiable risk factors. For
example, the Pooled Cohort risk equations from the American
College of Cardiology/American Heart Association use age,
race, sex, systolic blood pressure (SBP), antihypertensive
medication use, diabetes mellitus, cigarette smoking, and
total and high-density lipoprotein (HDL) cholesterol to
estimate 10-year predicted ASCVD risk.5
Identifying modifiable risk factors with the largest
relative contribution to the development of high ASCVD
risk may inform which of these factors to target for
primordial prevention and population health management.6
This is particularly important for blacks, a population with a
higher burden of modifiable risk factors including hyperten-
sion and diabetes mellitus and a higher average 10-year
predicted ASCVD risk compared to other race/ethnic
groups in the United States.7–9 Therefore, we identified
the contribution of changes in modifiable risk factors,
independent of aging, on developing high 10-year predicted
ASCVD risk (≥7.5%) in the Jackson Heart Study (JHS), a
cohort comprising exclusively blacks. As aging is an
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important, nonmodifiable ASCVD risk factor, we contrasted
changes in the modifiable risk factors versus the contribu-
tion of aging over the study period. Because high 10-year
predicted ASCVD risk increases with age, we conducted
secondary analyses for younger (age <50 years) and older
(age ≥50 years) adults, separately.8
Methods
Study Population
The JHS was designed to examine cardiovascular disease risk
in black men and women.10,11 The study enrolled 5306 blacks
in Jackson, MS between 2000 and 2004. Participants
completed study visits at baseline in 2000–2004 (visit 1)
and during follow-up in 2005–2008 (visit 2) and 2009–2012
(visit 3). The current analysis was restricted to 1987 JHS
participants who did not have a history of ASCVD, hyperten-
sion, or diabetes mellitus at visit 1. We excluded participants
who did not attend visit 3 (n=433) and those with missing
data needed to calculate 10-year predicted ASCVD risk at visit
1 or visit 3 using the Pooled Cohort risk equations (n=218).
Additionally, we excluded 221 participants with high 10-year
predicted ASCVD risk, defined as ≥7.5%, at visit 1. The
remaining 1115 JHS participants were analyzed (Figure 1).
The protocol for the JHS was approved by the institutional
review boards of the University of Mississippi Medical Center,
Jackson State University, and Tougaloo College. All partici-
pants provided written informed consent. The analysis of JHS
data for the current study was approved by the institutional
review board at the University of Alabama at Birmingham.
Data Collection
Data collected through interview-administered questionnaires
at visit 1 and visit 3 included age, sex, education, antihyper-
tensive medication use, and history of ASCVD defined by a
prior myocardial infarction, stroke, or coronary, carotid, or
peripheral revascularization procedure. Use of statin and
antidiabetes mellitus medication was collected through a pill
bottle review. Specifically, participants were asked to bring all
medications they took in the past 2 weeks to the study visit.
Drug names were recorded by trained staff. If a participant did
not bring all of their medications, a complete medication list
was obtained by a postexamination phone call to the
participant or their pharmacy. Data on smoking status was
collected at visit 1 and every 6 months thereafter during
follow-up via phone call. Smoking status at visit 3 was
determined based on the 6-month phone call closest to visit 3.
Blood pressure was measured 2 times during each visit
following a standardized protocol. The 2 blood pressure
measurements were averaged for analysis. Blood pressure
was measured using a random-zero sphygmomanometer
(Hawksley and Sons Ltd., Lancing, UK) at visit 1 and a
semiautomatic oscillometric device (Omron HEM-907XL,
Omron Healthcare Inc., Lake Forest, IL) at visit 3. As
described previously, the random-zero blood pressure mea-
surements were calibrated to the semiautomated device using
robust regression.12 Hypertension was defined as SBP
≥140 mm Hg, diastolic blood pressure (DBP) ≥90 mm Hg,
or self-reported antihypertensive medication use.
Fasting blood samples were collected during visits 1 and 3.
Serum glucose was measured using a glucose oxidase
method on a Vitros 250 or 950, Ortho-Clinical Diagnostics
analyzer. Hemoglobin A1c was measured using a TOSOH high-
performance liquid chromatography system. Triglycerides and
total and HDL cholesterol were measured using standard
techniques.13 Low-density lipoprotein cholesterol was calcu-
lated using the Friedewald equation.14 Diabetes mellitus was
defined by self-reported history with current use of oral
antidiabetes mellitus medication or insulin, fasting glucose
≥126 mg/dL, or hemoglobin A1c ≥6.5%.
10-Year Predicted ASCVD Risk
We calculated 10-year predicted ASCVD risk for black men
and women at visits 1 and 3 using the Pooled Cohort risk
equations (Table S1).5 These equations have been shown to
have good calibration and discrimination in several cohorts
including the JHS.5,15,16 The sex- and race-specific Pooled
Cohort risk equations include the following risk factors: age,
cigarette smoking, SBP, antihypertensive medication use,
diabetes mellitus, and total and HDL cholesterol. We defined a
10-year predicted ASCVD ≥7.5% as high; this is the level that
is used to denote consideration of statin initiation for primary
prevention of ASCVD in the American College of Cardiology/
American Heart Association Guideline on the Treatment of
Blood Cholesterol to Reduce Atherosclerotic Cardiovascular
Risk in Adults.3
Statistical Analysis
We calculated the distribution of 10-year predicted ASCVD
risk at visits 1 and 3. Participant characteristics at visits 1 and
3 were calculated for the overall population and for those with
and without high ASCVD risk at visit 3, separately. Two-
sample t tests and v2 tests, as appropriate, were used to
compare the characteristics for participants who did and did
not develop high ASCVD risk by visit 3.
We calculated the mean 10-year predicted ASCVD risk at
visits 1 and 3 and the change in ASCVD risk between these
visits. We recalculated the mean 10-year predicted ASCVD
risk at visit 3, assuming each risk factor in the Pooled Cohort
risk equations did not change from visit 1. For example, the
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mean 10-year predicted ASCVD risk at visit 3 was
calculated using participants’ ages at visit 1 and all other
risk factors from visit 3. This was repeated assuming (1)
SBP and antihypertensive medication use, (2) current
smoking, (3) diabetes mellitus, and (4) total and HDL
cholesterol, one at a time, did not change between visits 1
and 3. The increase in 10-year predicted ASCVD risk
attributable to aging and, separately, change in each risk
factor was calculated as the observed 10-year predicted
ASCVD risk at visit 3 minus the recalculated 10-year
predicted ASCVD risk, assuming each risk factor had not
changed from visit 1 (Figure S1, Equation 1). This was also
calculated as a percentage of the overall change in 10-year
predicted ASCVD risk between visits 1 and 3 and as a ratio
of the change in risk attributable to aging (Figure S1,
Equations 2 and 3, respectively). We recalculated the
percentage of participants with high 10-year predicted
ASCVD risk (≥7.5%) at visit 3 assuming age and each
modifiable risk factor in the Pooled Cohort risk equations,
one at a time, did not change from visit 1. We also
calculated the percent of the observed high 10-year
predicted ASCVD risk at visit 3 that was attributable to
participants aging and changes in modifiable risk factors,
overall and as a ratio of high 10-year predicted ASCVD risk
solely because of participants aging (Figure S1, Equations
4–6). A 1000-iteration bootstrap was used to calculate 95%
CI for the amount of the change in mean 10-year predicted
ASCVD risk and prevalence of high 10-year predicted
ASCVD risk attributable to aging and changes in modifiable
risk factors.17 Because the Pooled Cohort risk equations
were derived among adults ≥40 years of age, we performed
a sensitivity analysis restricted to JHS participants who
were ≥40 years of age at visit 1 (n=798). Analyses were
repeated within subgroups of age defined by <50 years and
Total Jackson Heart Study participants
(n=5,306)
No history of ASCVD at visit 1
(n=4,534)




Complete data on ASCVD risk model inputs at visit 1 and visit 3
(n=1,336)






History of ASCVD at visit 1
(n=772)
High ASCVD risk (≥7.5%) at visit 1
(n=221)
Missing data at visit 1 or 3
(n=218)
Did not attend visit 3
(n=443)
History of hypertension or 
diabetes at visit 1
(n=2,547)
Figure 1. Flowchart showing the eligibility criteria applied to participants in the Jackson
Heart Study. ASCVD indicates atherosclerotic cardiovascular disease.
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≥50 years. All analyses were conducted using SAS soft-
ware, Version 9.4 (SAS Institute, Inc., Cary, NC).
Results
The median time between visits 1 and 3 was 8.0 years (range
6.4–11.8 years). Among the 1115 JHS participants meeting
the inclusion criteria, 345 (30.9%) developed a high 10-year
predicted ASCVD risk at visit 3 (Figure 2). At visit 1,
participants who developed versus those who did not develop
a high 10-year predicted ASCVD risk at visit 3 were older,
more likely to be male, have less than a high school
education, smoke cigarettes, and take statins (Table 1, top
panel). Those who developed high 10-year predicted ASCVD
risk also had a higher mean SBP, DBP, and total and low-
density lipoprotein cholesterol at visit 1 than their counter-
parts who did not develop high 10-year predicted ASCVD risk
at visit 3. At visit 3, 41.5% and 9.4% of participants had
developed hypertension and diabetes mellitus, respectively
(Table 1, bottom panel).
The mean 10-year predicted ASCVD risk increased from
2.41% (95% CI 2.28%, 2.53%) at visit 1 to 5.87% (95% CI
5.57%, 6.18%) at visit 3 (Table 2). When calculating 10-year
predicted ASCVD risk at visit 3 using participants’ ages at visit
1 and all other risk factor levels from visit 3, the mean 10-year
predicted ASCVD risk was 3.45% (95% CI 3.24%, 3.65%). Aging
alone accounted for 69.8% (95% CI 67.5%, 72.1%) of the
overall increase in 10-year predicted ASCVD risk between
visits 1 and 3. Change in SBP and initiation of antihyperten-
sive medication and incident diabetes mellitus accounted for
35.3% (95% CI 32.4%, 38.0%) and 17.3% (95% CI 14.2%,
20.5%), respectively, of the overall increase in mean 10-year
predicted ASCVD risk.
Overall, 30.9% of JHS participants included in the analysis
developed a high 10-year predicted ASCVD risk at visit 3
(Table 3). Assuming no change in participants’ ages from visit
1, 12.5% (95% CI 10.5%, 14.4%) of participants would have a
high 10-year ASCVD risk at visit 3. Aging alone accounted for
59.7% (95% CI 54.2%, 65.1%) of the development of a high
10-year predicted ASCVD risk between visits 1 and 3.
Assuming no change in SBP or initiation of antihypertensive
medication by visit 3, 20.8% (95% CI 18.5%, 23.1%) of
participants would still have developed a high 10-year
predicted ASCVD risk. Changes in SBP and antihypertensive
medication initiation accounted for 32.8% (95% CI 27.0%,
38.2%) of the overall percentage of participants developing
high 10-year predicted ASCVD risk at visit 3. The incidence of
diabetes mellitus accounted for a smaller percentage of the
development of high 10-year predicted ASCVD risk, and
changes in smoking and total and HDL cholesterol did not
account for any of the development of high 10-year predicted
ASCVD risk. Results were similar when the analysis was
restricted to participants ≥40 years of age at visit 1 (Tables
S2 and S3).
Figure 2. Distribution of 10-year ASCVD risk over an 8-year time period (visit 1–visit 3) in the overall population (n=1115). ASCVD indicates
atherosclerotic cardiovascular disease.
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Table 1. Participant Characteristics at Visit 1 (Top Panel) and Visit 3 (Bottom Panel), Overall and by 10-Year Predicted ASCVD Risk
at Visit 3 (n=1115)
All Participants
(N=1115)
10-Year ASCVD Risk at Visit 3
<7.5% (N=770) ≥7.5% (N=345) P Value
Characteristics at visit 1
Age, y 45.2 (9.5) 41.6 (8.0) 53.0 (7.6) <0.001
Age group, y
<30 70 (6.3) 69 (9.0) 1 (0.3) <0.001
30 to 39 247 (22.2) 235 (30.5) 12 (3.5)
40 to 49 454 (40.7) 348 (45.2) 106 (30.7)
50 to 59 266 (23.9) 114 (14.8) 152 (44.1)
≥60 78 (7.0) 4 (0.5) 74 (21.4)
Male sex 375 (33.6) 207 (26.9) 168 (48.7) <0.001
Less than high school education 66 (5.9) 35 (4.5) 31 (9.0) 0.006
Current smoker 105 (9.4) 57 (7.4) 48 (13.9) <0.001
BMI, kg/m2 30.8 (7.2) 31.0 (7.4) 30.5 (6.8) 0.32
SBP, mm Hg 116.7 (10.2) 115.2 (10.1) 120.1 (9.6) <0.001
DBP, mm Hg 74.1 (7.2) 73.5 (7.0) 75.4 (7.4) <0.001
Total cholesterol, mg/dL 193.3 (37.7) 188.9 (36.9) 203.1 (37.7) <0.001
HDL cholesterol, mg/dL 51.6 (13.3) 52.1 (13.1) 50.5 (13.6) 0.06
LDL cholesterol, mg/dL 124.3 (35.7) 120.8 (35.2) 132.2 (35.5) <0.001
Statin use 19 (1.8) 6 (0.8) 13 (4.1) <0.001
Characteristics at visit 3
Age, y 53.2 (9.4) 49.7 (7.9) 61.1 (7.5) <0.001
Age group, y
<30 7 (0.6) 7 (0.9) 0 (0.0) <0.001
30 to 39 81 (7.3) 79 (10.3) 2 (0.6)
40 to 49 316 (28.3) 293 (38.1) 23 (6.7)
50 to 59 439 (39.4) 316 (41.0) 123 (35.7)
60 to 69 222 (19.9) 73 (9.5) 149 (43.2)
≥70 50 (4.5) 2 (0.3) 48 (13.9)
Male sex 375 (33.6) 207 (26.9) 168 (48.7) <0.001
Less than high school education 64 (5.8) 32 (4.2) 32 (9.4) 0.001
Current smoker 100 (9.0) 46 (6.0) 54 (15.7) <0.001
BMI, kg/m2 32.1 (7.3) 32.5 (7.8) 31.1 (6.2) 0.002
SBP, mm Hg 121.2 (14.2) 118.2 (12.7) 128.0 (14.9) <0.001
DBP, mm Hg 76.3 (10.0) 75.7 (9.4) 77.7 (10.9) 0.002
Antihypertensive medication 355 (31.8) 182 (23.6) 173 (50.1) <0.001
Hypertension 463 (41.5) 241 (31.3) 222 (64.3) <0.001
Diabetes mellitus 105 (9.4) 28 (3.6) 77 (22.3) <0.001
Total cholesterol, mg/dL 199.7 (37.2) 196.3 (35.7) 207.4 (39.3) <0.001
HDL cholesterol, mg/dL 58.0 (15.3) 58.6 (15.5) 56.5 (14.9) 0.04
LDL cholesterol, mg/dL 123.9 (34.0) 120.9 (32.7) 130.5 (36.0) <0.001
Statin use 133 (13.1) 73 (10.5) 60 (18.8) <0.001
Numbers in the table are mean (SD) or n (percentage). ASCVD indicates atherosclerotic cardiovascular disease; BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.
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Change in 10-Year ASCVD Risk by Age
Among 771 participants <50 years of age at visit 1, 119
(15.4%) developed high 10-year predicted ASCVD risk at visit
3 compared with 226 of 344 (65.7%) participants ≥50 years
of age at visit 1 (Figure S2). Characteristics of participants
who developed and did not develop a high 10-year predicted
ASCVD risk at visit 3 by age category are provided in Table S4
(participants <50 years of age) and Table S5 (participants
≥50 years of age).
Compared with the other modifiable risk factors, increasing
SBP and initiation of antihypertensive medication accounted
for a larger amount of the increase in mean 10-year predicted
ASCVD risk between visits 1 and 3 among both participants
Table 2. Increase in Mean 10-Year Predicted ASCVD Risk Between Visits 1 and 3, Overall and Attributable to Aging and Changes
in Modifiable Risk Factors
Risk Factor
Mean 10-Year Predicted
ASCVD Risk (95% CI)
Increase in 10-Year ASCVD Risk (Visit 3—Visit 1) Because of Aging and Changes






to Aging (95% CI)
Observed risk at visit 1 2.41 (2.28, 2.53) . . . . . . . . .
Observed risk at visit 3 5.87 (5.57, 6.18) . . . . . . . . .
Overall increase (visit 3 minus visit 1) 3.46 (3.25, 3.69) . . . 100 (reference) . . .
Risk factor at visit 1 used for prediction
Age 3.45 (3.24, 3.65) 2.42 (2.32, 2.54) 69.8 (67.5, 72.1) 100 (reference)
SBP or initiation of antihypertensive medication 4.65 (4.41, 4.89) 1.22 (1.09, 1.37) 35.3 (32.4, 38.0) 50.6 (45.3, 55.7)
Smoking 5.88 (5.58, 6.17) 0.01 (0.07, 0.06) † †
Diabetes mellitus 5.27 (5.02, 5.53) 0.60 (0.48, 0.74) 17.3 (14.2, 20.5) 24.8 (20.1, 29.8)
Total and HDL cholesterol 6.10 (5.79, 6.42) 0.23 (0.29, 0.16) † †
Bootstrapping was used to quantify the 95% CIs of the 10-year predicted ASCVD risk estimates. The percentages in the column labeled “Percentage of overall increase (95% CI)” do not add
up to 100% because they are not mutually exclusive. ASCVD indicates atherosclerotic cardiovascular disease; HDL, high-density lipoprotein; SBP, systolic blood pressure.
*The overall increase in 10-year predicted ASCVD risk attributable to aging and the change in each risk factor, separately, calculated as the 10-year predicted ASCVD risk at visit 3 minus
the recalculated 10-year predicted ASCVD risk at visit 3, assuming the risk factor in the row had not changed from visit 1. The equations used to calculate percentage of overall increase
and the ratio as compared to aging are shown in Figure S1.
†Smoking and cholesterol did not contribute to the increase in mean 10-year predicted ASCVD risk increase. See column labeled “Increase* (95% CI)”.
Table 3. Percentage of Participants Developing High Predicted ASCVD Risk Between Visits 1 and 3, Overall, and Attributable to
Aging and Modifiable Risk Factors (n=1115)
High 10-Year Predicted
ASCVD Risk (95% CI)
High 10-Year ASCVD Risk Because of Individual Risk Factors
Percent (95% CI)
Percent Over Observed
High Risk (95% CI)
Ratio as Compared
to Aging (95% CI)
Observed
Visit 1 0.0 . . . . . . . . .
Visit 3 30.9 (28.3, 33.4) . . . . . . . . .
Overall increase (visit 3 minus visit 1) 30.9 (28.3, 33.4) . . . 100 (reference) . . .
Risk factor at visit 1 used for prediction
Age 12.5 (10.5, 14.4) 18.5 (16.3, 20.9) 59.7 (54.2, 65.1) 100 (reference)
SBP or initiation of antihypertensive medication 20.8 (18.5, 23.1) 10.1 (8.2, 12.1) 32.8 (27.0, 38.2) 54.9 (45.9, 63.8)
Smoking 31.3 (28.7, 33.8) 0.4 (1.1, 0.1) * *
Diabetes mellitus 27.0 (24.3, 29.2) 3.9 (2.8, 5.0) 12.8 (9.6, 16.5) 21.4 (15.7, 27.4)
Total and HDL cholesterol 31.7 (28.8, 34.3) 0.8 (2.0, 0.3) * *
The equations used to calculate the percent over observed high risk and the ratio as compared to aging are shown in Figure S1. Bootstrapping was used to quantify the 95% CIs of the
percentage developing a high 10-year ASCVD predicted risk. High predicted ASCVD risk is defined at ≥7.5%. The percentages in the column labeled “Percent over observed high risk (95%
CI)” do not add up to 100% because they are not mutually exclusive. ASCVD indicates atherosclerotic cardiovascular disease; HDL, high-density lipoprotein; SBP, systolic blood pressure.
*Percentage of overall change because of smoking and cholesterol not contributing to the development of high 10-year predicted ASCVD risk.
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<50 and ≥50 years of age (Table S6). Assuming no change in
SBP and no initiation of antihypertensive medication by visit 3,
6.4% (95% CI 4.5%, 7.9%) and 53.2% (95% CI 47.7%, 58.4%) of
participants <50 years and ≥50 years, respectively, would
have developed a high 10-year predicted ASCVD risk
(Table S7). Among participants <50 years of age, increasing
SBP and antihypertensive medication initiation accounted for
58.8% (95% CI 49.2%, 68.8%) of the development of high 10-
year predicted ASCVD risk, which was similar to the
contribution of aging alone (65.5% [95% CI 56.7%, 73.6%]).
Among participants ≥50 years of age, aging alone accounted
for 56.6% (95% CI 50.5%, 63.5%), with each modifiable risk
factor contributing less than 20% of the development of high
10-year predicted ASCVD risk at visit 3.
Discussion
In the current prospective study of blacks with a mean age of
45 years and 10-year predicted ASCVD risk <7.5%, 1 out of
3 participants developed a 10-year predicted ASCVD risk
≥7.5% over an 8-year follow-up period. Aging was the largest
contributor, accounting for 60% of the development of high
10-year predicted ASCVD risk. Increases in SBP or initiation of
antihypertensive medication was the modifiable risk factor
that contributed the highest proportion to the development of
high 10-year predicted ASCVD risk, especially among partic-
ipants <50 years of age at baseline. In participants age
<50 years, the contribution of increases in SBP or initiation of
antihypertensive medication to 10-year predicted ASCVD risk
was similar to the contribution of aging alone. Incident
diabetes mellitus and changes in smoking status and total and
HDL cholesterol had a smaller contribution to the develop-
ment of high 10-year predicted ASCVD risk.
In the current study, ASCVD risk increased substantially
over 8 years of follow-up and aging accounted for more
than two thirds of this increase. This finding indicates that
many people will develop high ASCVD risk simply by aging
alone, potentially becoming candidates for treatment with a
statin or aspirin.1,3 It has been previously shown that all
adults will eventually develop a 10-year predicted ASCVD
risk ≥7.5% despite maintaining an optimal risk factor
profile.18 For example, among adults with optimal modifiable
risk factor levels (ie, no diabetes mellitus and not a smoker,
total and HDL cholesterol of 170 and 50 mg/dL, respec-
tively, and SBP of 110 mm Hg without antihypertensive
medication use), the development of high ASCVD risk will
occur at ages 65, 70, and 75 years for non-Hispanic white
men, black men and women, and non-Hispanic white
women, respectively.18 However, as aging did not explain
all of the increase in ASCVD risk in the current study,
preventing modifiable risk factors will delay the development
of high ASCVD risk.
Hypertension is a well-established and modifiable ASCVD
risk factor that disproportionately affects blacks.7,19,20 Blacks
have higher mean SBP beginning in childhood and develop
hypertension earlier in life compared with other race/ethnic
groups in the United States.19,21,22 Over the 8 years of follow-
up in the current study, the mean SBP increased by
5 mm Hg and 41.5% of participants developed hyperten-
sion. These changes accounted for a substantial proportion of
the increase in mean 10-year predicted ASCVD risk and over
half of the participants with high 10-year predicted ASCVD
risk at visit 3 had also developed hypertension. In the current
study, the impact of increasing SBP and incident hypertension
was greater among blacks <50 years at baseline, and this
effect was similar in size to the contribution from aging alone.
Results from the current analysis suggest that preventing
increases in mean SBP and incident hypertension in young
blacks could reduce the mean 10-year predicted ASCVD risk
by a magnitude similar to the effect of aging alone.
Diabetes mellitus is a well-established ASCVD risk factor
and has a high prevalence in blacks.23,24 In the current
prospective study, 10% of participants developed diabetes
mellitus. At the population level, incident diabetes mellitus
contributed less than changes in SBP or initiation of
antihypertensive medication to the development of high 10-
year predicted ASCVD risk. As most people with diabetes
mellitus have high ASCVD risk, it remains an important target
for primary prevention of ASCVD.25 Furthermore, there are
common behavioral determinants of both hypertension and
diabetes mellitus including diet and physical activity.26,27
Interventions focused on these health behaviors have the
potential to reduce both increases in SBP and the develop-
ment of diabetes mellitus.
Smoking and blood cholesterol levels are well-established
ASCVD risk factors.28,29 However, changes in these risk
factors did not contribute to the development of high 10-
year predicted ASCVD risk among blacks in the current
analysis. In JHS, the percentage of participants who were
smokers did not change substantially throughout the study
period. This is consistent with data indicating that very few
individuals start smoking after the age of 25 years.30
Participants who developed high 10-year ASCVD risk were
more likely to be smokers at baseline compared with those
who did not develop high 10-year ASCVD risk. This suggests
that population-wide benefits may be present with smoking
cessation interventions. Similarly, participants who devel-
oped high 10-year ASCVD risk had higher total and lower
HDL cholesterol levels at visit 1 compared to their
counterparts who did not develop high risk. Although levels
of total cholesterol increased during follow-up, levels of HDL
cholesterol also increased. This may explain the lack of
contribution of changes in cholesterol levels to the incidence
of high ASCVD risk because high HDL cholesterol is
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associated with a lower ASCVD risk.31 Also, increases in total
cholesterol during follow-up may have been attenuated
because of statin initiation. Statin use is not incorporated into
ASCVD risk prediction equations, and the accuracy of these
equations among individuals taking statins has not been well
investigated.
There are many reasons why it is important to prevent the
development of high 10-year predicted ASCVD risk. Prior
studies have reported that most ASCVD events occur among
people with 10-year predicted ASCVD risk ≥7.5%.15,32 Also,
predicted ASCVD risk is increasingly being used in clinical
practice guidelines.1–3 For example, guideline recommenda-
tions for the use of statins and aspirin for primary prevention
of ASCVD are, in part, based on an individual’s 10-year
predicted ASCVD risk.1,3 Therefore, preventing the develop-
ment of high 10-year predicted ASCVD risk through targeting
modifiable risk factors could delay medication initiation. In
turn, this could reduce medication costs, polypharmacy and
risk of adverse events, and contribute to increased quality of
life into older ages.
Healthcare reform in the United States has placed
increasing emphasis on population health management.33
Population health managers are often challenged with decid-
ing on which interventions to implement, and who should
receive them, to optimize the health of the overall population.
The current study suggests that developing high ASCVD risk
could be averted for a substantial percentage of blacks
through interventions that prevent increases in SBP and the
need for initiation of antihypertensive medication. These may
include physical activity, limiting sodium and alcohol intake,
weight loss, and the Dietary Approaches to Stop Hypertension
(DASH) diet, which have all been shown to lower blood
pressure.34,35
The current study has several strengths. These include the
prospective study design, a large sample of blacks, and the
use of standardized protocols to measure ASCVD risk factors,
blood pressure, and other components of the Pooled Cohort
risk equations at 2 time points nearly 8 years apart. The JHS
is a community-based sample of exclusively blacks in 3
counties surrounding Jackson, MS. Therefore, the results may
not be generalizable to other race/ethnic groups or geo-
graphic regions.
In summary, 1 out of 3 blacks in the JHS developed a
high 10-year predicted ASCVD risk over a median follow-up of
8 years. Increases in SBP and initiation of antihypertensive
medication were the modifiable risk factors accounting for the
largest percentage of the development of high ASCVD risk.
Among adults <50 years, increases in SBP or initiation of
antihypertensive medication contributed to the development
of high ASCVD risk similar to aging 8 years. These results
support the need for the development and implementation of
population health management interventions to reduce the
incidence of high ASCVD risk among blacks by preventing
increases in SBP and incident hypertension.
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Table S1. Estimation of race- and gender-specific ASCVD risk using the ASCVD Pooled Cohort risk equations.1  
 Equations parameters* 
 S0(t) at 5 years2 
S0(t) at 10 
years 
Mean 
score Individual score 
Participants not taking antihypertensive medications 
Black women 0.98194 0.9533 86.61 = 17.114 × ln(age) + 0.94 × ln(TC) - 18.92 × ln(HDL-C) + 4.475 × ln(age) × ln(HDL-C) + 
27.82 × ln(SBP) - 6.087 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.809 × ln(SBP) (+ 0.549 if current 
smoker) (+ 0.645 if diabetes) 
Participants taking antihypertensive medications 
Black women 0.98194 0.9533 86.61 = 17.114 × ln(age) + 0.94 × ln(TC) - 18.92 × ln(HDL-C) + 4.475 × ln(age) × ln(HDL-C) + 
29.291 × ln(SBP) - 6.432 × ln(age) × ln(SBP) (+ 0.691 if current smoker) (+ 0.874 if diabetes) 
Black men 0.95726 0.8954 19.54 = 2.469 × ln(age) + 0.302 × ln(TC) - 0.307 × ln(HDL-C) + 1.916 × ln(SBP) (+ 0.549 if current 
smoker) (+ 0.645 if diabetes) 
ASCVD: atherosclerotic cardiovascular disease; HDL-C: high-density lipoprotein cholesterol; SBP: systolic blood pressure; TC: total cholesterol. 
* Final risk estimation is calculated as: 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑃𝑃𝑃𝑃𝑟𝑟𝑟𝑟 = 1 − 𝐴𝐴0(𝑃𝑃)𝑒𝑒













Table S2. Increase in mean 10-year predicted ASCVD risk (%) between visits 1 and 3, overall, and attributable to aging and 
changes in modifiable risk factors among participants age ≥ 40 years at visit 1 (n=798).  
 Increase in 10-year ASCVD risk (visit 3 – visit 1) due to 
changes in each risk factor 
Risk Factor Mean 10-year 
predicted ASCVD 






Ratio as compared 
to aging 
(95% CI) 
Observed risk at visit 1 3.01 (2.86, 3.15)    
Observed risk at visit 3 7.31 (6.97, 7.67)    
Overall increase (visit 3 minus visit 1) 4.31 (4.05, 4.61)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 4.34 (4.10, 4.59) 2.98 (2.84, 3.14) 69.1 (66.8, 71.7) 100 (reference) 
SBP or initiation of antihypertensive medication 5.84 (5.57, 6.16) 1.47 (1.30, 1.66) 34.2 (31.1, 37.6) 49.5 (44.1, 55.2) 
Smoking 7.31 (6.98, 7.65) 0.00 (-0.08, 0.09) ǂ ǂ 
Diabetes 6.54 (6.27, 6.86) 0.78 (0.61, 0.97) 18.0 (14.8, 21.5) 26.1 (20.9, 31.5) 
Total and HDL cholesterol 7.55 (7.22, 7.91) -0.24 (-0.32, -0.15) ǂ ǂ 
ASCVD= atherosclerotic cardiovascular disease, CI= confidence interval, HDL= high-density lipoprotein, SBP = systolic blood pressure. 
*The overall increase in 10-year predicted ASCVD risk attributable to aging and the change in each risk factor, separately, calculated as 
the 10-year predicted ASCVD risk at visit 3 minus the re-calculated 10-year predicted ASCVD risk at visit 3 assuming a risk factor hadn’t 
changed from visit 1. 
The equations used to calculate percentage of overall increase and the ratio as compared to aging are shown in Figure S1. 
ǂ Smoking and cholesterol did not contribute to the increase mean 10-year predicted ASCVD risk increase. 
Bootstrapping was used to quantify the 95% CIs of the 10-year predicted ASCVD risk estimates. 













Table S3. Percentage of participants ≥ 40 years of age developing high predicted ASCVD risk between Jackson Heart Study visits 1 
and 3, overall, and attributable to aging and modifiable risk factors. 
 High 10-year predicted ASCVD Risk 
(95% CI) 
 Risk Factor 






observed high risk 
(95% CI) 
Ratio as compared 
to aging 
(95% CI) 
Observed     
     Visit 1 0    
Visit 3 41.6 (38.2, 45.1)    
Overall increase (visit 3 minus visit 1) 41.6 (38.2, 45.1)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 16.9 (14.4, 19.3) 24.7 (21.6, 27.8) 59.3 (54.0, 64.4) 100 (reference) 
SBP or initiation of antihypertensive medication 28.9 (25.9, 32.0) 12.7 (10.0, 15.2) 30.4 (24.9, 36.2) 51.3 (42.5, 60.0) 
Smoking 41.9 (38.6, 45.3) -0.3 (-1.1, 0.5) ǂ ǂ 
Diabetes 36.3 (33.2, 39.9) 5.3 (3.6, 6.8) 12.7 (8.9, 16.2) 21.3 (15.2, 27.8) 
Total and HDL cholesterol 42.7 (39.5, 46.1) -1.1 (-2.8, 0.4) ǂ ǂ 
The equations used to calculate the percent over observed high risk and the ratio as compared to aging are shown in Figure S1. 
ASCVD= atherosclerotic cardiovascular disease, CI= confidence interval, HDL= high-density lipoprotein, SBP = systolic blood pressure. 
ǂ Percentage of overall change due to smoking and cholesterol not contributing to the development of high 10-year predicted ASCVD risk. 
Bootstrapping was used to quantify the 95% CIs of the percentage developing a high 10-year ASCVD predicted risk. 
High predicted ASCVD risk is defined at ≥ 7.5%. 














Table S4. Participant characteristics at visit 1 (top panel) and visit 3 (bottom panel) overall and 
by 10-year predicted ASCVD risk at visit 3 among those age < 50 years (n=771). 
   10-year ASCVD risk at visit 3 








Characteristics at visit 1     
Age, years 40.3 (6.6) 39.5 (6.7) 44.4 (3.9) <0.001 
Age group, years    
<0.001 
 <30 70 (9.1) 69 (10.6) 1 (0.8) 
 30 – 39 247 (32.0) 235 (36.0) 12 (10.1) 
 40 – 49 454 (58.9) 348 (53.4) 106 (89.1) 
 50 – 59 0 (0.0) 0 (0.0) 0 (0.0) 
 ≥60  0 (0.0) 0 (0.0) 0 (0.0) 
Male sex, % 277 (35.9) 191 (29.3) 86 (72.3) <0.001 
Less than high school education, % 43 (5.6) 32 (4.9) 11 (9.2) 0.08 
Current smoker, % 82 (10.6) 50 (7.7) 32 (26.9) <0.001 
BMI, kg/m2 30.9 (7.2) 31.0 (7.5) 30.5 (5.7) 0.50 
SBP, mm Hg 116.1 (10.2) 115.0 (9.9) 121.9 (9.4) <0.001 
DBP, mm Hg 74.4 (7.2) 73.7 (7.1) 78.1 (6.5) <0.001 
Total cholesterol, mg/dL 189.3 (37.9) 187.1 (37.0) 201.2 (40.8) <0.001 
HDL cholesterol, mg/dL 50.5 (12.9) 51.5 (13.0) 45.0 (10.7) <0.001 
LDL cholesterol, mg/dL 121.9 (36.2) 119.9 (35.4) 133.0 (38.7) <0.001 
Statin use, % 6 (0.8) 3 (0.5) 3 (2.7) 0.05 
Characteristics at visit 3 
Age, years 48.4 (6.6) 47.6 (6.7) 52.6 (3.7) <0.001 
Age group, years     
 <30 7 (0.9) 7 (1.1) 0 (0.0) 
<0.001 
 30 – 39 81 (10.5) 79 (12.1) 2 (1.7) 
 40 – 49 316 (41.0) 293 (44.9) 23 (19.3) 
 50 – 59 366 (47.5) 272 (41.7) 94 (79.0) 
 60 – 69 1 (0.1) 1 (0.2) 0 (0.0) 
 ≥70  0 (0.0) 0 (0.0) 0 (0.0) 
Male sex, % 277 (35.9) 191 (29.3) 86 (72.3) <0.001 
Less than high school education, % 38 (5.0) 29 (4.5) 9 (7.7) 0.16 
Current smoker, % 78 (10.1) 45 (6.9) 33 (27.7) <0.001 
BMI, kg/m2 32.7 (7.7) 32.8 (7.9) 31.9 (6.2) 0.25 
SBP, mm Hg 120.2 (13.8) 118.3 (12.7) 130.8 (15.1) <0.001 
DBP, mm Hg 77.4 (10.0) 76.3 (9.4) 83.5 (11.1) <0.001 
Antihypertensive medication, % 232 (30.1) 159 (24.4) 73 (61.3) <0.001 
Hypertension, % 299 (38.8) 209 (32.1) 90 (75.6) <0.001 
Diabetes, % 68 (8.8) 27 (4.1) 41 (34.5) <0.001 
Total cholesterol, mg/dL 197.4 (37.5) 195.6 (36.3) 207.4 (42.3) 0.002 
HDL cholesterol, mg/dL 56.5 (15.2) 57.7 (15.4) 50.1 (12.6) <0.001 
LDL cholesterol, mg/dL 123.0 (34.7) 121.0 (33.4) 133.8 (39.5) <0.001 
Statin use, % 72 (10.4) 54 (9.2) 18 (17.5) 0.02 
Numbers in the table are mean (standard deviation) or n (percentage). BMI=body mass index, HDL= 
high-density lipoprotein, ASCVD= atherosclerotic cardiovascular disease, SBP =systolic blood 
pressure, DBP= diastolic blood pressure. 
 
  








Table S5. Participant characteristics at visit 1 (top panel) and visit 3 (bottom panel) overall and 
by 10-year predicted ASCVD risk at visit 3 among those age ≥ 50 years (n=344). 
   10-year ASCVD Risk at Visit 3 








Characteristics at visit 1     
Age, years 56.1 (4.4) 53.3 (2.7) 57.6 (4.4) <0.001 
Age group, years    
<0.001 
 <30 0 (0.0) 0 (0.0) 0 (0.0) 
 30 – 39 0 (0.0) 0 (0.0) 0 (0.0) 
 40 – 49 0 (0.0) 0 (0.0) 0 (0.0) 
 50 – 59 266 (77.3) 114 (96.6) 152 (67.3) 
 ≥60  78 (22.7) 4 (3.4) 74 (32.7) 
Male sex, % 98 (28.5) 16 (13.6) 82 (36.3) <0.001 
Less than high school education, % 23 (6.7) 3 (2.5) 20 (8.9) 0.02 
Current smoker, % 23 (6.7) 7 (5.9) 16 (7.1) 0.82 
BMI, kg/m2 30.6 (7.2) 30.8 (6.9) 30.5 (7.3) 0.75 
SBP, mm Hg 118.2 (10.2) 116.3 (10.9) 119.2 (9.6) 0.01 
DBP, mm Hg 73.5 (7.2) 72.6 (6.7) 74.0 (7.5) 0.11 
Total cholesterol, mg/dL 202.2 (35.8) 198.5 (35.2) 204.2 (36.0) 0.16 
HDL cholesterol, mg/dL 54.1 (13.8) 55.5 (13.4) 53.4 (14.1) 0.17 
LDL cholesterol, mg/dL 129.8 (33.8) 126.1 (33.5) 131.7 (33.8) 0.14 
Statin use, % 13 (4.1) 3 (2.6) 10 (4.9) 0.39 
Characteristics at visit 3 
Age, years 64.0 (4.5) 61.2 (2.9) 65.5 (4.5) <0.001 
Age group, years     
 <30 0 (0.0) 0 (0.0) 0 (0.0) 
<0.001 
 30 – 39 0 (0.0) 0 (0.0) 0 (0.0) 
 40 – 49 0 (0.0) 0 (0.0) 0 (0.0) 
 50 – 59 73 (21.2) 44 (37.3) 29 (12.8) 
 60 – 69 221 (64.2) 72 (61.0) 149 (65.9) 
 ≥70  50 (14.5) 2 (1.7) 48 (21.2) 
Male sex, % 98 (28.5) 16 (13.6) 82 (36.3) <0.001 
Less than high school education, % 26 (7.6) 3 (2.6) 23 (10.2) 0.01 
Current smoker, % 22 (6.4) 1 (0.8) 21 (9.3) 0.002 
BMI, kg/m2 30.8 (6.4) 31.1 (6.8) 30.6 (6.1) 0.55 
SBP, mm Hg 123.4 (14.8) 117.3 (12.9) 126.6 (14.7) <0.001 
DBP, mm Hg 73.9 (9.5) 72.4 (9.2) 74.7 (9.6) 0.03 
Antihypertensive medication, % 123 (35.8) 23 (19.5) 100 (44.2) <0.001 
Hypertension, % 164 (47.7) 32 (27.1) 132 (58.4) <0.001 
Diabetes, % 37 (10.8) 1 (0.8) 36 (15.9) <0.001 
Total cholesterol, mg/dL 205.0 (35.9) 200.5 (31.8) 207.3 (37.7) 0.09 
HDL cholesterol, mg/dL 61.2 (14.9) 63.6 (14.8) 59.9 (14.9) 0.03 
LDL cholesterol, mg/dL 125.9 (32.5) 120.2 (28.5) 128.9 (34.0) 0.02 
Statin use, % 61 (18.7) 19 (17.4) 42 (19.4) 0.76 
Numbers in the table are mean (standard deviation) or n (percentage). BMI=body mass index, HDL= 
high-density lipoprotein, ASCVD= atherosclerotic cardiovascular disease, SBP =systolic blood 













Table S6. Increase in mean 10-year predicted ASCVD risk between visits 1 and 3, overall, and attributable to aging and 
changes in modifiable risk factors among those age < 50 years (top panel) and ≥ 50 years (bottom panel). 
 
 Increase in 10-year ASCVD risk (visit 3 – visit 1) due to 
changes in each risk factor 
 Risk Factor 
Mean 10-year 
predicted ASCVD 






Ratio as compared 
to aging 
(95% CI) 
Age < 50 years  
Observed risk at visit 1 1.60 (1.50, 1.72)    
Observed risk at visit 3 4.02 (3.77, 4.31)    
Overall increase (visit 3 minus visit 1) 2.42 (2.22, 2.62)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 2.34 (2.17, 2.54) 1.68 (1.59, 1.77) 69.3 (66.8, 72.1) 100 (reference) 
SBP or initiation of antihypertensive medication 2.99 (2.82, 3.19) 1.02 (0.89, 1.17) 42.4 (38.9, 45.8) 61.1 (55.0, 67.9) 
Smoking 4.05 (3.81, 4.33) -0.03 (-0.08, 0.01) ǂ ǂ 
Diabetes 3.60 (3.39, 3.82) 0.42 (0.32, 0.54) 17.5 (13.8, 20.9) 25.2 (19.6, 31.2) 
Total and HDL cholesterol 4.24 (3.98, 4.53) -0.22 (-0.28, -0.16) ǂ ǂ 
Age ≥ 50 years   
Observed risk at Visit 1 4.22 (4.00, 4.41)    
Observed risk at Visit 3 10.02 (9.48, 10.62)    
Overall increase (visit 3 minus visit 1) 5.81 (5.31, 6.34)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 5.94 (5.52, 6.36) 4.08 (3.87, 4.33) 70.3 (66.8, 73.9) 100 (reference) 
SBP or initiation of antihypertensive medication 8.35 (7.92, 8.82) 1.67 (1.33, 2.03) 28.8 (24.1, 33.3) 40.9 (33.3, 49.1) 
Smoking 9.97 (9.45, 10.55) 0.05 (-0.11, 0.23) 0.9 (-1.9, 3.9) 1.3 (-2.7, 5.7) 
Diabetes 9.03 (8.57, 9.48) 1.00 (0.71, 1.37) 17.2 (12.7, 22.2) 24.4 (17.8, 32.4) 
Total and HDL cholesterol 10.26 (9.69, 10.90) -0.24 (-0.40, -0.08) ǂ ǂ 
ASCVD= atherosclerotic cardiovascular disease, CI= confidence interval, HDL= high-density lipoprotein, SBP = systolic blood pressure. 
*The overall increase in 10-year predicted ASCVD risk attributable to aging and the change in each risk factor, separately, calculated as 
the 10-year predicted ASCVD risk at visit 3 minus the re-calculated 10-year predicted ASCVD risk at visit 3 assuming a risk factor 
hadn’t changed from visit 1. 
The equations used to calculate percentage of overall increase and the ratio as compared to aging are shown in Figure S1. 
ǂ Smoking and cholesterol did not contribute to the increase mean 10-year predicted ASCVD risk increase. 
Bootstrapping was used to quantify the 95% CIs of the 10-year predicted ASCVD risk estimates. 
The percentages in the column labeled “Percentage of overall increase (95% CI)” do not add up to 100% because they are not mutually 
exclusive. 








Table S7. Percentage of participants age < 50 years (top panel) and ≥ 50 years (bottom panel) developing high predicted ASCVD risk 
between Jackson Heart Study visits 1 and 3 attributable to aging and modifiable risk factors. 
 High 10-year predicted ASCVD Risk 
(95% CI) 
 Risk Factor 






observed high risk 
(95% CI) 
Ratio as compared 
to aging 
(95% CI) 
Age < 50 years  
Observed     
Visit 1 0    
Visit 3 15.4 (12.8, 17.8)    
Overall increase (visit 3 minus visit 1) 15.4 (12.8, 17.8)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 5.3 (3.9, 6.9) 10.1 (8.0, 12.2) 65.5 (56.7, 73.6) 100 (reference) 
SBP or initiation of antihypertensive medication 6.4 (4.5, 7.9) 9.1 (7.1, 11.2) 58.8 (49.2, 68.8) 89.7 (75.8, 104.5) 
Smoking 15.8 (13.4, 18.3) -0.4 (-1.2, 0.1) ǂ ǂ 
Diabetes 11.8 (9.6, 13.7) 3.6 (2.5, 4.9) 23.5 (16.7, 31.7) 35.9 (25.7, 49.7) 
Total and HDL cholesterol 16.2 (13.6, 18.7) -0.8 (-2.1, 0.0) ǂ ǂ 
Age ≥ 50 years  
Observed     
Visit 1 0.0    
Visit 3 65.7 (60.2, 70.3)    
Overall increase (visit 3 minus visit 1) 65.7 (60.2, 70.3)  100 (reference)  
Risk factor at visit 1 used for prediction     
Age 28.5 (23.5, 33.1) 37.2 (32.0, 42.2) 56.6 (50.5, 63.5) 100 (reference) 
SBP or initiation of antihypertensive medication 53.2 (47.7, 58.4) 12.5 (8.4, 16.6) 19.0 (13.2, 25.0) 33.6 (24.0, 44.8) 
Smoking 66.0 (60.8, 70.6) -0.3 (-1.7, 0.6) ǂ ǂ 
Diabetes 61.0 (55.2, 66.0) 4.7 (2.6, 6.7) 7.1 (4.0, 10.6) 12.5 (6.9, 18.6) 
Total and HDL cholesterol 66.6 (61.4, 71.2) -0.9 (-4.1, 1.7) ǂ ǂ 
The equations used to calculate the percent over observed high risk and the ratio as compared to aging are shown in Figure S1. 
ASCVD= atherosclerotic cardiovascular disease, CI= confidence interval, HDL= high-density lipoprotein, SBP = systolic blood pressure. 
ǂ Percentage of overall change due to smoking and cholesterol not contributing to the development of high 10-year predicted ASCVD risk. 
Bootstrapping was used to quantify the 95% CIs of the percentage developing a high 10-year ASCVD predicted risk. 
High predicted ASCVD risk is defined at ≥ 7.5%. 
The percentages in the column labeled “Percent over observed high risk (95% CI)” do not add up to 100% because they are not mutually 
exclusive. 
 























Figure S1. Equations used to calculate the percentage of overall change in 10-year predicted ASCVD risk due to risk 
factors and ratio as compared to aging. 
Increase in 10-year predicted ASCVD risk due to change in risk factor (Equation 1)  
 
Percentage of overall  
change in 10-year predicted 
ASCVD risk due to risk factor  10-year predicted ASCVD risk at visit 3 – 10-year predicted ASCVD risk visit 1 
 
Ratio comparing change in 10-
year predicted ASCVD risk due  
to risk factor versus aging 
100 
 
ASCVD= atherosclerosis cardiovascular disease. 
 
High 10-year predicted ASCVD 
risk due to change in risk factor  
Percentage of overall change due to risk factor (Equation 2) 
Percentage of overall change due to aging (Equation 2 for age) 
100 
 
10-year predicted ASCVD risk at visit 3 – 10-year predicted ASCVD risk at visit 3  
                                             if no change in risk factor 
 
Increase in 10-year predicted 
ASCVD risk due to change in 
risk factor  
High 10-year predicted ASCVD risk due to change in risk factor (Equation 4)  
 
Percent high 10-year ASCVD 
risk due to risk factor  
Percent high 10-year predicted ASCVD risk at 
   
Equations used to calculate contribution of risk factors on mean 10-year ASCVD predicted risk increase. 
Equations used to calculate contribution of risk factors on the development of high 10-year predicted ASCVD risk. 
Percent with high 10-year predicted ASCVD risk at visit 3 – Percent with high 10-year predicted ASCVD  




Ratio comparing change due 
to risk factor versus aging  
Percent with high 10-year predicted ASCVD risk due to risk factor (Equation 5)  
 








































Figure S2. Histograms of 10-year ASCVD risk at visit 1 and visit 3 among participants 
< 50 years of age (top panel, n=771) and ≥ 50 years of age (bottom panel, n=344). 
 








ASCVD: atherosclerotic cardiovascular disease, SD: standard deviation 
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